Abstract
The release and re-uptake of theories of schizophrenia is a process nearly as universal as neurotransmission itself, since every neurotransmitter has been proposed, at one time or another, as contributing to the etiology of the disease. There are theories implicating acetylcholine, noradrenaline, serotonin, GABA, and dopamine. Certainly this phenomenon underscores the relevance of basic research, since each new discovery of neuroregulatory substances brings with it possibilities for theorizing and experimenting about schizophrenia.
Keywords
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
References
Abood, L. G., and Biel, J. H., 1962, Anticholinergic psychotomimetic agents, Int. Rev. Neurobiol. 4:217–273.
Aghajanian, G. K., Foote, W. E., and Sheard, M. H., 1968, Lysergic acid diethylamide: Sensitive neuronal units in the midbrain raphe, Science 161:706–708.
Aghajanian, G. K., Foote, W. E., and Sheard, M. H., 1970, Action of psychotogenic drugs on single midbrain raphe neurons, J. Pharmacol. Exp. Ther. 171:178–187.
Alzheimer, A., 1897, Beitrage zur pathologischen Anatomie der Hirnrinde und zur anatomischen Grundlage einiger Psychosen, Monatschr. Psychiatr. Neurol. 2:82–120.
AndÉn, N.-E., 1972, Dopamine turnover in the corpus striatum and the limbic system after treatment with neuroleptic and anti-acetylcholine drugs, J. Pharm. Pharmacol. 24:905–906.
Angrist, B. M., and Gershon, S., 1970, The phenomenology of experimentally induced amphetamine psychosis — preliminary observations, Biol. Psychiatry 2:95–107.
Atsmon, A., Blum, I., Wijsenbeek, H., Maoz, B., Steiner, M., and Ziegelman, G., 1971, The short-term effects of adrenergic-blocking agents in a small group of psychotic patients, Psychiatr. Neurol. Neurochir. 74:251–258.
Bidder, T. G., Mandel, L. R., Ahn, H. S., Vandeeuvel, W. J. A., and Walker, R. W., 1974, Blood and urinary dimethyltryptamine concentrations in acute psychotic disorders, Lancet 1:165.
Bleuler, E., 1950, Dementia Praecox or the Group of Schizophrenias, International University Press, New York (orig. pub. 1911).
Bloom, F. E., Hoffer, B. J., and Siggins, G. R., 1971, Studies on norepinephrine-containing afferents to purkinje cells of rat cerebellum. II. Sensitivity of purkinje cells to norepinephrine and related substances administered by microiontophoresis, Brain Res. 25:523–534.
Boring, E. G., 1950, A History of Experimental Psychology, Apple ton-Century-Crofts, New York.
Boullin, D. J., Coleman, M., and O’Brien, R. A., 1970, Abnormalities in platelet 5-hydroxytryptamine efflux in patients with infantile autism, Nature 226:371.
Bowers, M. B., Jr., 1973, 5-Hydroxyindoleacetic acid (5-HIAA) and homovanillic acid (HVA) following probenecid in acute psychotic patients treated with phenothiazines, Psychopharmacologia 28:309–318.
Bradley, P. B.. 1963, Phenothiazine derivatives, in: Physiological Pharmacology, Vol. 1 (W. Root and F. Hofmann, eds.), pp. 417–477, Academic Press, New York.
Bunney, B. S., and Aghajanian, G. K., 1975, Antipsychotic drugs and central dopaminergic neurons: A model for predicting therapeutic efficacy and extrapyramidal side effects, in: Prediction in Psychopharmacology (A. Sudilovsky, S. Gershon, and B. Beer, eds.), Raven Press, New York.
Bürki, H. R., Eichenbergen, E., Sayers, A. C., and White, T. G., 1975, Clozapine and the dopamine hypothesis of schizophrenia: A critical appraisal, Pharmakopsychiatrie 8:115–121.
Burkman, A. M., 1973, Biological activity of apomorphine fragments: Dissociation of emetic and stereotypicaleffects Neuropharmacology 12:83–85.
Callaway, E., 1959, The influence of amobarbital (amylbarbitone) and methamphetamine on the focus of attention, J. Ment. Sci. 105:382–392.
Callaway, E., and Band, R. J., 1958, Some psychopharmacological effects of atropine, Arch. Neurol. Psychiatry 79:91–102.
Callaway, E., and Stone, G., 1970, Drugs and Behavior, Wiley, New York.
Carlsson, A., and Lindqvist, M., 1963, Effect of chlorpromazine and haloperidol on the formation of 3-methoxytyramine and normetanephrine in mouse brain, Acta Pharmacol. (Kbh.) 20:140–144.
Carroll, B. J., Frazer, A., Schless, A., and Mendels, J., 1973, Cholinergic reversal of manic symptoms, Lancet 1:427–428.
Carpenter, W. T., Fink, E. B., Narasimhachari, N., and Himwich, H. E., 1975, A test of the transmethylation hypothesis in acute schizophrenic patients, Am. J. Psychiatry 132:1067–1071.
Childs, B., Worden, F., Matthysse, S., and Gershon, E., (eds.), 1976, Frontiers in psychiatric genetics, Neurosciences Research Program Bulletin No. 14, pp. 1–107.
Clement-Cormier, Y. C., Kebabian, J. W., Petzold, G. L., and Greengard, P., 1974, Dopamine-sensitive adenylate cyclase in mammalian brain: A possible site of action of antipsychotic drugs, Proc. Natl. Acad. Sci. U.S.A. 71:1113–1117.
Cole, J. O., and Clyde, D. J., 1961, Extrapyramidal side effects and clinical response to the phenothiazines, Rev. Can. Biol. 20:565–574.
Creveling, C. R., and Daly, J. W., 1967, Identification of 3, 4-dimethoxyphenylethylamine from schizophrenic urine by mass spectrometry, Nature 216:190–191.
Cromwell, R. L., and Dokecki, P. R., 1968, Schizophrenic language: A disattention interpretation, in: Developments in Applied Psycholinguistics Research (S. Rosenberg and J. H. Koplin, eds.), pp. 209–260, Macmillan, New York.
Davison, K., and Bagley, C. R., 1969, Schizophrenia-like psychoses associated with organic disorders of the central nervous system: A review of the literature, in: Current Problems in Neuropsychiatry: Schizophrenia, Epilepsy, the Temporal Lobe (R. N. Herrington, ed.), pp. 113–184, Br. J. Psychiatry Spec. Publ. No. 4, Headley Bros., Ashford, Kent.
Day, H., and Thomas, E. L., 1967, Effect of amphetamine on selective attention, Percept. Mot. Skills 29:1119–1125.
Domino, E. F., 1964, Neurobiology of phencyclidine (Sernyl), a drug with an unusual spectrum of pharmacological activity, Int. Rev. Neurobiol. 6:303–347.
Downing, R. W., Ebert, J. N., and Shubrooks, S. J., 1963, Effects of phenothiazines on the thinking of acute schizophrenics, Percept. Mot. Skills 17:511–520.
Dunlap, C. B., 1924, Dementia praecox. Some preliminary observations on brains from carefully selected cases, and a consideration of certain sources of error, Am. J. Psychiatry 3:403–421.
Dunner, D. L., Cohn, C. K., Weinshilboum, R. M., and Wyatt, R. J., 1973, The activity of dopamine beta-hydroxylase and methionine-activating enzyme in blood of schizophrenic patients, Biol. Psychiatry 6:215–220.
Ellinwood, E. H., Jr., Sudilovsky, A., and Nelson, L. M., 1973, Evolving behavior in the clinical and experimental amphetamine (model) psychosis, Am. J. Psychiatry 130:1088–1093.
Frederiksen, P. K., 1975, Baclofen in the treatment of schizophrenia, Lancet 1:702–703.
Friedhoff, A. J., and Van Winkle, E., 1962, The characteristics of an amine found in the urine of schizophrenic patients, J. Nerv. Ment. Disord. 135:550–555.
Friedhoff, A. J., Schweitzer, J. W., and Miller, J. 1972, Biosynthesis of mescaline and N-acetylmescaline by mammalian liver, Nature 237:454–455.
Fulcher, J. H., Gallagher, W. J., and Pfeiffer, C. C., 1957, Comparative lucid intervals after amobarbital, CO2, and arecoline in the chronic schizophrenic, Arch. Neurol. Psychiatry 78:392–395.
Ganong, W. F., 1974, Brain mechanisms regulating the secretion of the pituitary gland, in: The Neurosciences: Third Study Program (F. O. Schmitt and F. G. Worden, eds.), pp. 549–563, M.I.T. Press, Cambridge, Massachusetts.
Garelis, E., Gillin, J. C., Wyatt, R. J., and Neff, N., 1975, Elevated blood serotonin concentrations in unmedicated chronic schizophrenic patients: A preliminary study, Am. J. Psychiatry 132:184–186.
Gerlach, J., Thorsen, K., and Fog, R., 1975, Extrapyramidal reactions and amine metabolites in cerebrospinal fluid during haloperidol and clozapine treatment of schizophrenic patients, Psychopharmacologia 40:341–350.
Goldstein, M., Freedman, L. S., Ebstein, R. P., and Park, D. H., 1974, Studies on dopamine-beta-hydroxylase in mental disorders, J. Psychiatr. Res. 11:205–210.
Green, D. M., and Swets, J. A., 1974, Signal Detection Theory and Psychophysics, Krueger, New York.
Groves, P. M., Wilson, C. J., Young, S. J., and Rebec, G. V., 1975, Self-inhibition by dopaminergic neurons, Science 190:522–529.
Gupta, G. P., and Dhawan, B. N., 1965, Blockade of apomorphine pecking with phenothiazines, Psychopharmacologia 8:120–130.
Hemmel, H. T., 1968, Regulation of internal body temperature, Annu. Rev. Physiol. 30:644–710.
Hornykiewicz, O., 1966, Dopamine (3-hydroxytyramine) and brain function, Pharm. Rev. 18:925–964.
Ingle, D., 1975, Focal attention in the frog: Behavioral and physiological correlates, Science 188:1033–1034.
Iversen, L. L., Bird, E. D., Mackay, A. V. P., and Rayner, C. N., 1974, Analysis of glutamate decarboxylase in post-mortem brain tissue in Huntington’s chorea, J. Psychiatr. Res. 11:255–256.
Janssen, P. S. J., Niemegeers, C.J. E., Schellekens, H. K. L., and Lenaerts, F. M., 1967, Is it possible to predict the clinical effects of neuroleptic drugs (major tranquilizers) from animal data? IV. An improved experimental design for measuring the inhibitory effects of neuroleptic drugs on amphetamine- or apomorphine-induced “chewing” and “agitation” in rats, Arzneim. Forsch. 17:841–854.
Janowsky, D. S., El-Yousef, M. K., Davis, J. M., and Sekerke, H. J., 1973a, Parasympathetic suppression of manic symptoms by physostigmine, Arch. Gen. Psychiatry 28:542–547.
Janowsky, D. S., El-Yousef, M. K., Sekerke, J., and Davis, J. M., 1973b, Provocation of schizophrenic symptoms by intravenous administration of methylphenidate, Arch. Gen. Psychiatry 28:185–191.
Janowsky, D. S., El-Yousef, and Davis, J. M., 1973c, Antagonistic effects of physostigmine and methylphenidate in man, Am. J. Psychiatry 130:1370–1376.
Kaada, B., and Bruand, H., 1960, Blocking of the cortically induced behavioral attention (orienting) response by chlorpromazine, Psychopharmacologia 1:372–388.
Kakimoto, Y., Sano, I., Kanazawa, A., Tsujio, T., and Kaneko, Z., 1967, Metabolic effects of methionine in schizophrenic patients pretreatecl with a monoamine oxidase inhibitor, Nature 216:1110–1111.
Karczmar, A. G., 1970, Central cholinergic pathways and their behavioral implications, in: Principles of Psychopharmacology (W. G. Clark and J. Del Giudice, eds.), pp. 57–86, Academic Press, New York.
Karobath, M. E., 1975, Dopamin-Rezeptor-Blockade, ein möglicher Wirkungsmechanismus antipsychotichen Drogen, Pharmakopsychatrie 8:151–161.
Karobath, M., and Leitich, H., 1974, Antipsychotic drugs and dopamine-stimulated adenylate cyclase prepared from corpus striatum of rat brain, Proc. Natl. Acad. Sci. U.S.A. 71:2915–2918.
Kety, S. S., 1967, Current biochemical approaches to schizophrenia, N. Engl. J. Med. 276:325–331.
Kety, S. S., 1971, The biogenic amines in the central nervous system: Their possible roles in arousal, emotion and learning, in: The Neurosciences: SecondStudy Program (F. O. Schmitt, ed.), pp. 324–336, Rockefeller University Press, New York.
Key, B. J., 1961, The effect of drugs on discrimination and sensory generalization of auditory stimuli in rats, Psychopharmacologia (Berlin) 2:352–362.
Killam, E. K., and Killam, K. F., 1959, Phenothiazine — pharmacologic studies, in: The Effect of Pharmacologic Agents on the Nervous System (F. J. Braceland, ed.), Chapter 37, p. 245, Williams and Wilkins, Baltimore.
Kornetsky, C., and Bain, G., 1965, The effects of chlorpromazine and pentobarbital on sustained attention in the rat, Psychopharmacologia (Berlin) 8:277–284.
Koslow, S. H., Post, R., Goodwin, F., and Gillin, C., 1975, Mass fragmentographic identification and quantification of 5-methoxytryptamine (5MT) in human cerebrospinal fluid (CSF), Abstracts, 5th Ann. Mtg., Soc. for Neurosci. p. 361.
Kraepelin, E., 1919, Dementia Praecox and Paraphrenia, E. and S. Livingstone, Edinburgh (orig. pub. 1913).
Lang, P. J., and Buss, A. H., 1965, Psychological deficit in schizophrenia: II. Interference and activation, J. Abnorm. Psychol. 70:77–106.
Lipinski, J. F., Mandel, L. R., Ahn, H. S., Vandeeuvel, W. J. A., and Walker, R. W., 1974, Blood dimethyltryptamine concentrations in psychotic disorders, Biol. Psychiatry 9:89–91.
Maayani, S., Weinstein, H., Cohen, S., and Sokolovsky, M., 1973, Acetylcholine-like molecular arrangement in psychomimetic anticholinergic drugs, Proc. Natl. Acad. Sci. U.S.A. 70:3103–3107.
Maickel, R. P., Braunstein, M. C., Mlynn, M., Snodgrass, W. R., and Webb, R. W., 1974, Behavioral, biochemical and pharmacological effects of chronic dosage of phenothiazine tranquilizers in rats, in: The Phenothiazines and Structurally Related Drugs (I. S. Forrest, C. J. Carr, and E. Usdin, eds.), pp. 593–602, Raven Press, New York.
Mandel, L., Ahn, H. S., Vandeeuvel, W. J. A., and Walker, R. W., 1972, Indoleamine-N-methyltransferase in human lung, Biochem. Pharmacol. 21:1197–1200.
Mandell, A. J., 1974, The role of adaptive regulation in the pathophysiology of psychiatric disease, J. Psychiatr. Res. 11:173–179.
Mandell, A. J., and Morgan, M., 1971, Indole(ethyl)amine-N-methyltransferase in human brain, Nature (London), New Biol. 230:85–87.
Matthysse, S., 1973, Antipsychotic drug actions: A clue to the neuropathology of schizophrenia? Fed. Proc. 32:200–205.
Matthysse, S., 1974a, Implications of feedback control in catecholamine neuronal systems, in: Frontiers in Catecholamine Research (E. Usdin and S. Snyder, eds.), pp. 1139–1142, Pergamon Press, Oxford.
Matthysse, S., 1974b, Schizophrenia: Relationships to dopamine transmission, motor control, and feature extraction, in: The Neurosciences: Third Study Program (F. O. Schmitt and F. G. Worden, eds.), pp. 733–737, M.I.T. Press, Cambridge, Massachusetts.
Matthysse, S., 1975, Neuronal models of transmitter balance, in: Neurotransmitters and Autocoid Balances Regulating Behavior (E. F. Domino and J. Davis, eds.), pp. 229–233, Edwards Bros., Ann Arbor.
Matthysse, S., and Haber, S., 1975, Animal models of schizophrenia, in: Model Systems in Biological Psychiatry (D. J. Ingle and H. M. Shein, eds.), pp. 4–25, M.I.T. Press, Cambridge, Massachusetts.
Matthysse, S., and Kety, S. S., 1974, Catecholamines and schizophrenia, J. Psychiatr. Res. 11:1–369.
Matthysse, S., and Lipinski, J., 1975, Biochemical aspects of schizophrenia, Annu. Rev. Med. 26:551–565.
Mcghie, A., and Chapman, J., 1961, Disorders of attention and perception in early schizophrenia, Brit. J. Med. Psychol. 34:103–116.
Meltzer, H. Y., Sachar, E. J., and Frantz, A. G., 1974, Serum prolactin levels in unmedicated schizophrenic patients, Arch. Gen. Psychiatry 31:564–569.
Meltzer, H. Y., Daniels, S., and Fang, V. S., 1975, Clozapine increases rat serum prolactin levels, Life Sci. 17:339–342.
Mettler, F. A., 1955, Perceptual capacity, functions of the corpus striatum and schizophrenia, Psychiatr. Q. 29:89–111.
Meyer, A., 1963, Psychoses of obscure pathology, in: Greenfield’s Neuropathology, 2nd ed. (W. Blackwood, ed.), pp. 621–635, Williams and Wilkins, Baltimore.
Miller, R. J., 1974, The action of neuroleptic drugs on dopamine-stimulated adenosine cyclic 3’, 4’-monophosphate production in rat neostriatum and limbic forebrain, Mol. Pharmacol. 10:759–766.
Miller, R. J., and Hiley, C. R., 1974, Anti-muscarinic properties of neuroleptics and drug-induced Parkinsonism, Nature 248:596–597.
Mirsky, A., and Kornetsky, C., 1975, On the dissimilar effects of drugs on the digit symbol substitution and continuous performance tests Psychopharmacologia (Berlin) 5:161–177.
Mirsky, A., Tecce, J., Harman, N., and Oshima, H., 1975, EEG correlates of impaired attention performance under secobarbital and chlorpromazine in the monkey, Psychopharmacologia (Berlin) 41:35–41.
Mountcastle, V. B., 1975, The view from within: Pathways to the study of perception, Johns Hopkins Med. J. 136:109–131.
Myers, R. D., 1970, The role of hypothalamic transmitter factors in the control of body temperature, in: Physiological and Behavioral Temperature Regulation (J. H. Hardy, A. P. Gagge, and J. A. J. Stolwijk, eds.), Charles C. Thomas, Springfield, Illinois.
Nash, H., 1962, Psychologic effects of amphetamines and barbiturates, J. Nerv. Ment. Disord. 134:203–217.
Nielsen, J., and Goldstein, L., 1972, Improvement of performance on an attention task with chronic nicotine treatment in rats, Psychopharmacologia 26:347–360.
Nishimura, T., and Gjessing, L. R., 1965, Failure to detect 3, 4-dimethoxyphenylethylamine and bufotenine in the urine from a case of periodic catatonia, Nature 206:963–964.
Orzack, M. H., and Kornetsky, C., 1966, Attention dysfunction in chronic schizophrenia, Arch. Gen. Psychiatry 14:323–326.
Orzack, M. H., Kornetsky, C., and Freeman, H., 1967, The effects of daily. administration of carphenazine on attention in the schizophrenic patient, Psychopharmacologia (Berlin) 11:31–38.
Osmond, H., and Smythies, J., 1952, Schizophrenia: A new approach, J. Ment. Sci. 98:309–315.
Perry, T. L., Hansen, S., Maougall, L., and Schwartz, C. J., 1966, Urinary amines in chronic schizophrenia, Nature 212:146–148.
Persson, T., and Roos, B.-E., 1969, Acid metabolites from monoamines in CSF of chronic schizophrenics, Br. J. Psychiatry 115:95–98.
Petti Grew, J. D., and Daniels, J. D., 1973, Gamma-aminobutyric acid antagonism in visual cortex: Different effects on simple, complex and hypercomplex neurons, Science 182:81–83.
Plum, F., 1972, Neuropathological findings, in: Prospects for Research in Schizophrenia (S. S. Kety and S. Matthysse, eds.), Neurosciences Research Program Bulletin No. 10, pp. 370–507.
Pollin, W., 1972, The pathogenesis of schizophrenia. Arch. Gen. Psychiatry 27:29–37.
Pollin, W., Cardon, P. V., Jr., and Kety, S. S., 1961, Effects of amino acid feedings in schizophrenic patients treated with iproniazid, Science 133:104–105.
Post, R. M., and Goodwin, F. K., 1975, Time-dependent effects of phenothiazines on dopamine turnover in psychiatric patients, Science 190:488–489.
Pugh, L. A., 1968, Response time and electrodermal measures in chronic schizophrenia: The effects of chlorpromazine, J. Nerv. Ment. Disord. 146:62–70.
Quarton, G., and Talland, G., 1962, The effect of methamphetamine and pentobarbital on two measures of attention, Psychopharmacologia 3:66–71.
Randrup, A., and Munkvad, I., 1974, Pharmacology and physiology of stereotyped behavior, J. Psychiatr. Res. 11:1–10.
Rappaport, M., Rogers, N., Reynolds, S., and Weinmann, R., 1966, Comparative ability of normal and chronic schizophrenic subjects to attend to competing voice messages: Effects of method of presentation, message load and drugs, J. Nerv. Ment. Disord. 143:16–27.
Rimon, R., Roos, B.-E., Rakkolainen, V., and Alanen, Y., 1971, The content of 5-HIAA and HVA in the CSF of patients with acute schizophrenia, J. Psychosom. Res. 15:375–378.
Roberts, E., 1972, An hypothesis suggesting that there is a defect in the GABA system in schizophrenia, in: Prospects for Research on Schizophrenia (S. S. Kety and S. Matthysse, eds.), Neurosciences Research Program Bulletin No. 10, pp. 370–507.
Rose, D., and Blakemore, C., 1974, Effects of bicuculline on functions of inhibition in visual cortex, Nature 249:375–377; erratum, p. 869.
Rosenbaum, G., Cohen, B. D., Luby, E. D., Gottlieb, J. S., and Yelen, D., 1959, Comparison of Sernyl with other drugs: Simulation of schizophrenic performance with Sernyl, LSD-25, and amobarbital (Amytal) sodium. I. Attention, motor function and proprioception, Arch. Gen. Psychiatry 1:651–656.
Rotrosen, J., Wallach, M. B., Angrist, B., and Gershon, S., 1972, Antagonism of apomorphine-induced stereotypy and emesis in dogs by thioridazine, haloperidol and pimozide, Psychopharmacologia 26:185–194.
Rowntree, D. W., Nevin, S., and Wilson, A., 1950, The effects of diisopropylfluorophosphonate in schizophrenia and manic depressive psychosis, J. Neurol. Neurosurg. Psychiatry 13:47–62.
Saavedra, J. M., and Axelrod, J., 1972, Psychotomimetic N-methylated tryptamines: Formation in brain in vivo and in vitro, Science 175:1365–1366.
Saavedra, J. M., and Axelrod, J., 1973, Effect of drugs on the tryptamine content of rat tissues, J. Pharmacol. Exp. Ther. 185:523–529.
Sachar, E. J., 1971, Growth hormone responses in depressive illness, Arch. Gen. Psychiatry 25:263–269.
Sachar, E. J., Gruen, P. H., Karasu, T. B., Altman, N., and Frantz, A. G., 1975, Thioridazine stimulates prolactin secretion in man, Arch. Gen. Psychiatry 32:885–886.
Sachar, E. J., Gruen, P. H., Altman, N., Halpern, F. S., and Frantz, A. G., 1976, The use of neuroendocrine techniques in psychopharmacological research, in: Hormones, Behavior and Psychopathology (E.J. Sachar, ed.), pp. 161–176, Raven Press, New York.
Salzinger, K., 1957, Shift in judgment of weights as a function of anchoring stimuli and instructions in early schizophrenics and normals, J. Abnorm. Soc. Psychol. 55:43–49.
Salzinger, K., Portnoy, S., Pisoni, D. B., and Feldman, R. S., 1970, The immediacy hypothesis and response-produced stimuli in schizophrenic speech, J. Abnorm. Psychol. 76:258–264.
Schelkunov, E. L., 1967, Integrated effect of psychotropic drugs on the balance of cholino-, adreno-, and serotoninergic processes in the brain as a basis of their gross behavioral and therapeutic actions, Act. Nerv. Super. 9:207–217.
Sedvall, G., Fyro, B., Nyback, H., Wiesel, F. A., and Wode-Helgodt, B., 1974, Mass fragmentometric determination of homovanillic acid in lumbar cerebrospinal fluid of schizophrenic patients during treatment with antipsychotic drugs, J. Psychiatr. Res. 11:75–80.
Seeman, P., and Lee, T., 1975, Antipsychotic drugs: Direct correlation between clinical potency and presynaptic action on dopamine neurons, Science 188:1217–1219.
Shakow, D., 1962, Segmental set, Arch. Gen. Psychiatry 6:1–17.
Siggins, G. R., Hoffer, B. J., and Ungerstedt, U., 1974, Electrophysiological evidence for involvement of cyclic adenosine monophosphate in dopamine responses of caudate neurons, Life Sci. 15:779–792.
Snyder, S. H., Banerjee, S. P., Yamamura, H. I., and Greenberg, D., 1974a, Drugs, neurotransmitters, and schizophrenia, Science 184:1243–1253.
Snyder, S. H., Greenberg, D., and Yamamura, H. I., 1974B, Antischizophrenic drugs: Affinity for muscarinic cholinergic receptor sites in the brain predicts extrapyramidal effects, J. Psychiatr. Res. 11:91–95.
Spielmeyer, W., 1930, The problem of the anatomy of schizophrenia, J. Nerv. Dis. 72:241–244.
Stabenau, J. R., Creveling, C. R., and Daly, J., 1970, The “pink spot,” 3,4-dimethoxyphenylethylamine, common tea, and schizophrenia, Am. J. Psychiatry 127:611–616.
Stawarz, R. J., Robinson, S., Sulser, F., and Dingell, J. V., 1974, On the significance of the increase of homovanillic acid (HVA) caused by antipsychotics in corpus striatum and limbic forebrain, Fed. Proc. 33:246.
Stein, L., and Wise, C. D., 1971, Possible etiology of schizophrenia: Progressive damage to the noradrenergic reward system by 6-hydroxydopamine, Science 171:1032–1036.
Sutton, S., and Zubin, J., 1965, Effect of sequence on reaction time in schizophrenia, in: Behavior, Aging and the Nervous System: Biological Determinants of Speed of Behavior and Its Change with Age (J. E. Birren and A. T. Welford, eds.), Charles C Thomas, Springfield, Illinois.
Swazey, J. P., 1974, Chlorpromazine in Psychiatry: A Study of Therapeutic Innovation, p. 113, M.I.T. Press, Cambridge, Massachusetts.
Szara, S., 1956, Dimethyltryptamine: Its metabolism in man; the relation of its psychotic effect to serotonin metabolism, Experientia 12:441–442.
Szara, A., 1967, Hallucinogenic amines and schizophrenia (with a brief addendum on N-dimethyltryptamine), in: Amines and Schizophrenia (H. E. Himwich, S. S. Kety, and J. R. Smythies, eds.), pp. 181–197, Pergamon Press, Oxford.
Takesada, M., Kakimoto, Y., Sano, I., and Kaneko, Z., 1963, 3, 4-Dimethoxyphenylethy-lamine and other amines in the urine of schizophrenic patients, Nature 199:203–204.
Teuber, H. L., 1972, Effects of focal brain lesions, in: Prospects for Research on Schizophrenia (S. S. Kety and S. Matthysse, eds.), Neurosciences Research Program Bulletin No. 10, pp. 381–385.
Turner, W. J., and Merlis, S., 1959, Effects of some indolealkylamines in man, Arch. Neurol. Psychiatry 81:121–129.
Valzelli, L., 1973, Psychopharmacology: An Introduction to Experimental and Chemical Principles, p. 217, Spectrum, Flushing, New York.
Vogt, C., and Vogt, O., 1952, Proceedings of the First International Congress on Neuropathology, Vol. 1, p. 515, Rosenberg and Sellier, Torino, Italy.
Von Studnitz, W., and Nyman, G. E., 1965, Excretion of 3, 4-dimethoxyphenylethylamine in schizophrenia, Acta Psychiatr. Scand. 41:117–121.
Waldbaum, J. K., Sutton, S., and Kerr, J., 1975, Shift of sensory modality and reaction time in schizophrenia, in: Experimental Approaches to Psychopathology (M. Kietzman, S. Sutton, and J. Zubin, eds.), pp. 167–176, Academic Press, New York.
Warburton, D. M., and Brown, K., 1972, The facilitation of discrimination performance by physostigmine sulphate, Psychopharmacologia (Berlin) 27:275–284.
Weil-Malherbe, H., and Szara, S. I., 1971, The Biochemistry of Functional and Experimental Psychoses, pp. 148–155, Charles C. Thomas, Springfield, Illinois.
Wiesel, F.-A., and Sedvall, G., 1975, Effect of antipsychotic drugs on homovanillic acid levels in striatum and olfactory tubercle of the rat, Eur. J. Pharmacol. 30:364–367.
Weiss, B., 1970, Amphetamine and the temporal structure of behavior, in: Amphetamine and Related Compounds (F. Costa and S. Garrattini, eds.), Raven Press, New York.
Weiss, B., and Laties, V. G., 1962, Enhancement of human performance by caffeine and amphetamines, Pharmacol. Rev. 14:1.
Wise, C. D., Baden, M. M., and Stein, L., 1974, Post-mortem measurement of enzymes in human brain: Evidence of a central noradrenergic deficit in schizophrenia, J. Psychiatr. Res. 11:185–198.
Wolf, A., and Cowen, D., 1949, Pathology, in: Selective Partial Ablation of the Frontal Cortex (A. Mettler, ed.), pp. 453–476, Hoeber Press, New York.
Woolley, D. W., 1957, Serotonin in mental disorders, in: Hormones, Brain Function and Behavior (H. Hoagland, ed.), pp. 127–146, Academic Press, New York.
Wyatt, R. J., Mandel, L. R., Ahn, H. S., Walker, R. W., and Vandeeuvel, W. J. A., 1973a, Gas-chromatographic-mass spectrometric isotope dilution determination of N,N-dimethyltryptamine concentrations in normal and psychiatric patients, Psychopharmacologia 31:265–270.
Wyatt, R. J., Saavedra, J. M., and Axelrod, J., 1973b, A dimethyltryptamine-forming enzyme in human blood, Am. J. Psychiatry 130:754–760.
Wyatt, R. J., Saavedra, J. M., Belmaker, R., Cohen, S., and Pollin, W., 1973C, The dimethyltryptamine forming enzyme in blood platelets: A study in monozygotic twins discordant for schizophrenia, Am. J. Psychiatry 130:1359–1361.
Wyatt, R. J., Schwartz, M. A., Erdelyi, E., and Barchas, J. D., 1975, Dopamine ß-hydroxylase activity in brains of chronic schizophrenic patients, Science 187:368–370.
Wynne, R. D., and Kornetsky, C., 1960, The effect of chlorpromazine and secobarbital on the reaction times of chronic schizophrenics, Psychopharmacologia 1:294–302.
Yaryura-Tobias, J. A., Diamond, B., and Merlis, S., 1970, The action of L-DOPA on schizophrenic patients (a preliminary report), Curr. Ther. Res. 12:528–531.
Yorkston, N. J., Zakimku, S. A., Malik, M. K. U., Morrisson, R. C., and Havard, C. W. H., 1974, Propanolol in the control of schizophrenic symptoms, Br. Med. J. 4:633–635. (see also pp. 614–615).
Zahn, T. P., Rosenthal, D., and Shakow, D., 1973, Effect of irregular preparatory intervals on reaction time in schizophrenia, J. Abnorm. Soc. Psychol. 67:44–52.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1978 Plenum Press, New York
About this chapter
Cite this chapter
Matthysse, S., Sugarman, J. (1978). Neurotransmitter Theories of Schizophrenia. In: Iversen, L.L., Iversen, S.D., Snyder, S.H. (eds) Handbook of Psychopharmacology. Springer, Boston, MA. https://doi.org/10.1007/978-1-4613-4042-3_7
Download citation
DOI: https://doi.org/10.1007/978-1-4613-4042-3_7
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4613-4044-7
Online ISBN: 978-1-4613-4042-3
eBook Packages: Springer Book Archive